A pilot study: potential role of nutrient vitamin D in prostate cancer patients with rising PSA after definitive therapy

被引：0
|
作者：
Choo, R.
Woo, T.
Veith, R.
Jamieson, M.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
[3] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：250 / 250
页数：1
相关论文
共 50 条
  • [21] A phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi, RS
    Derksen, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 405S - 405S
  • [22] A Tissue Biomarker Panel Predicting Systemic Progression after PSA Recurrence Post-Definitive Prostate Cancer Therapy
    Nakagawa, Tohru
    Kollmeyer, Thomas M.
    Morlan, Bruce W.
    Anderson, S. Keith
    Bergstralh, Eric J.
    Davis, Brian J.
    Asmann, Yan W.
    Klee, George G.
    Ballman, Karla V.
    Jenkins, Robert B.
    PLOS ONE, 2008, 3 (05):
  • [23] Young age to predict for transient elevation in PSA after definitive stereotactic body radiation therapy for prostate cancer.
    Blacksburg, Seth
    Katz, Aaron
    Witten, Matthew R.
    Clancey, Owen
    Haas, Jonathan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [24] A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy
    Sottile, Antonino
    Ortega, Cinzia
    Berruti, Alfredo
    Mangioni, Monica
    Saponaro, Sara
    Polo, Alessandra
    Prati, Veronica
    Muto, Giovanni
    Aglietta, Massimo
    Montemurro, Filippo
    ONCOLOGY LETTERS, 2012, 3 (04) : 819 - 824
  • [25] Role of statins and PSA nadir after androgen-deprivation therapy in overall survival of patients with metastatic prostate cancer
    Siddiqui, Salma
    Durbin-Johnson, Blythe P.
    Yap, Stanley A.
    White, Ralph W. deVere
    Ghosh, Paramita M.
    CANCER RESEARCH, 2019, 79 (13)
  • [26] Analysis of the clinical utility of the use of salvage brachytherapy in patients who have a rising PSA after definitive external beam radiation therapy
    D'Amico, AV
    UROLOGY, 1999, 54 (02) : 201 - 203
  • [27] Photodynamic therapy for recurrent prostate cancer after radiotherapy: A pilot study
    Arokianathan, TR
    Whitelaw, DE
    Lees, WR
    Chang, SSC
    Gillams, A
    Ripley, P
    Payne, H
    Emberton, M
    Bown, SG
    BRITISH JOURNAL OF CANCER, 1998, 78 : 8 - 8
  • [28] Effect of Patient Demographic Characteristics and Radiation Timing on PSA Reduction in Patients Treated With Definitive Radiation Therapy for Prostate Cancer
    Gupta, Apar
    Vernali, Steven
    Rand, Alexander E.
    Agarwal, Ankit
    Qureshi, Muhammad M.
    Hirsch, Ariel E.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (04) : 364 - 369
  • [29] Evaluation of agreement rates between radionuclide bone scintigraphy and radioimmunoscintigraphy with indium-111-capromab pendetide (Prostascint) in patients with rising PSA after definitive prostate cancer treatment
    Thomas, CT
    Montie, JE
    Sandler, HS
    Zasadny, KR
    Wahl, RL
    RADIOLOGY, 2000, 217 : 568 - 569
  • [30] A phase II trial of celecoxib in PSA recurrent prostate cancer after definitive radiation therapy (XRY) or radical prostatectomy (RP)
    Derksen, E
    Wallen, E
    Pruthi, R
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 199 (03) : S100 - S101
12345